Skip to main content
Top
Published in: Tumor Biology 11/2016

01-11-2016 | Original Article

Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression

Authors: Ailin Li, Weiwei Zhang, Huifang Xia, Yuan Miao, Haijing Zhou, Xiupeng Zhang, Qianze Dong, Qingchang Li, Xueshan Qiu, Enhua Wang

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

The role of Crk-associated substrate (CAS) family members in regulating invasion and metastasis has been described in several cancers. As the fourth member of the CAS family, CASS4 is also related with positive lymph node metastasis and poor prognosis in lung cancer. However, the underlying mechanisms and downstream effectors of CASS4 in the development and progression of non-small cell lung cancer (NSCLC) remain unclear. In this study, CASS4 overexpression inhibited E-cadherin expression and enhanced invasion in NSCLC cell line transfected with CASS4 plasmid, while CASS4 depletion upregulated E-cadherin expression and inhibited invasion in NSCLC cell line transfected with CASS4 siRNA. The effect of CASS4 overexpression in facilitating invasion of NSCLC cells was reversed by restoring E-cadherin expression, which indicates that CASS4 may promote invasion by inhibiting E-cadherin expression. Subsequent immunohistochemistry results confirmed that CASS4 overexpression correlated with loss of E-cadherin expression. We next investigated the phosphorylation levels of focal adhesion kinase (FAK), p38, extracellular signal-related kinase (ERK), and AKT after CASS4 plasmid or CASS4 siRNA transfection. CASS4 facilitated AKT (Ser473) phosphorylation. Treatment with an AKT phosphorylation inhibitor reversed the increased invasive capacity and downregulation of E-cadherin protein induced by CASS4 overexpression. Taken together, the present results indicate that CASS4 may promote NSCLC invasion by activating the AKT signaling pathway, thereby inhibiting E-cadherin expression.
Literature
3.
go back to reference Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci: CMLS. 2010;67(7):1025–48.CrossRefPubMed Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci: CMLS. 2010;67(7):1025–48.CrossRefPubMed
4.
go back to reference Deneka A, Korobeynikov V, Golemis EA. Embryonal Fyn-associated substrate (EFS) and CASS4: the lesser-known CAS protein family members. Gene. 2015;570(1):25–35.CrossRefPubMedPubMedCentral Deneka A, Korobeynikov V, Golemis EA. Embryonal Fyn-associated substrate (EFS) and CASS4: the lesser-known CAS protein family members. Gene. 2015;570(1):25–35.CrossRefPubMedPubMedCentral
5.
go back to reference Jiang WG et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35(Suppl):S244–75.CrossRefPubMed Jiang WG et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35(Suppl):S244–75.CrossRefPubMed
6.
go back to reference Tikhmyanova N, Golemis EA. NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One. 2011;6(7):e22102.CrossRefPubMedPubMedCentral Tikhmyanova N, Golemis EA. NEDD9 and BCAR1 negatively regulate E-cadherin membrane localization, and promote E-cadherin degradation. PLoS One. 2011;6(7):e22102.CrossRefPubMedPubMedCentral
7.
go back to reference Kong C et al. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One. 2011;6(7):e22666.CrossRefPubMedPubMedCentral Kong C et al. NEDD9 is a positive regulator of epithelial-mesenchymal transition and promotes invasion in aggressive breast cancer. PLoS One. 2011;6(7):e22666.CrossRefPubMedPubMedCentral
8.
go back to reference Miao Y et al. Expression of p130cas, E-cadherin and beta-catenin and their correlation with clinicopathological parameters in non-small cell lung cancer: p130cas over-expression predicts poor prognosis. Folia Histochem et Cytobiol/Pol Acad Sci Pol Histochem Cytochemical Soc. 2012;50(3):392–7.CrossRef Miao Y et al. Expression of p130cas, E-cadherin and beta-catenin and their correlation with clinicopathological parameters in non-small cell lung cancer: p130cas over-expression predicts poor prognosis. Folia Histochem et Cytobiol/Pol Acad Sci Pol Histochem Cytochemical Soc. 2012;50(3):392–7.CrossRef
9.
go back to reference Miao Y et al. Overexpression of NEDD9 is associated with altered expression of E-cadherin, beta-catenin and N-cadherin and predictive of poor prognosis in non-small cell lung cancer. Pathol Oncol Res: POR. 2013;19(2):281–6.CrossRefPubMed Miao Y et al. Overexpression of NEDD9 is associated with altered expression of E-cadherin, beta-catenin and N-cadherin and predictive of poor prognosis in non-small cell lung cancer. Pathol Oncol Res: POR. 2013;19(2):281–6.CrossRefPubMed
10.
go back to reference Miao Y et al. Overexpression and cytoplasmic accumulation of Hepl is associated with clinicopathological parameters and poor prognosis in non-small cell lung cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(1):107–14.CrossRef Miao Y et al. Overexpression and cytoplasmic accumulation of Hepl is associated with clinicopathological parameters and poor prognosis in non-small cell lung cancer. Tumour Biol: J Int Soc Oncodevelopmental Biol Med. 2013;34(1):107–14.CrossRef
12.
go back to reference Ciuffreda L et al. Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. Curr Pharm Des. 2014;20(24):3944–57.CrossRefPubMed Ciuffreda L et al. Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. Curr Pharm Des. 2014;20(24):3944–57.CrossRefPubMed
13.
go back to reference Strippoli R et al. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J Cell Sci. 2010;123(Pt 24):4321–31.CrossRefPubMed Strippoli R et al. p38 maintains E-cadherin expression by modulating TAK1-NF-kappa B during epithelial-to-mesenchymal transition. J Cell Sci. 2010;123(Pt 24):4321–31.CrossRefPubMed
14.
go back to reference Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 2013;8(3):e59083.CrossRefPubMedPubMedCentral Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 2013;8(3):e59083.CrossRefPubMedPubMedCentral
15.
go back to reference Hong KO et al. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J Exp Clin Cancer Res: CR. 2009;28:28.CrossRefPubMedPubMedCentral Hong KO et al. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J Exp Clin Cancer Res: CR. 2009;28:28.CrossRefPubMedPubMedCentral
16.
go back to reference Travis W, Brambilla E, Burke A, Marx A, Nicholson A. World Health Organization classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press; 2015. Travis W, Brambilla E, Burke A, Marx A, Nicholson A. World Health Organization classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon: IARC Press; 2015.
17.
18.
go back to reference Deng B, Tan QY, Wang RW, Jiang YG, Zhou JH, Huang W. P130cas is required for TGF-beta1-mediated epithelial-mesenchymal transition in lung cancer. Oncol Lett. 2014;8(1):454–60.PubMedPubMedCentral Deng B, Tan QY, Wang RW, Jiang YG, Zhou JH, Huang W. P130cas is required for TGF-beta1-mediated epithelial-mesenchymal transition in lung cancer. Oncol Lett. 2014;8(1):454–60.PubMedPubMedCentral
19.
go back to reference Cabodi S et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 2006;66(9):4672–80.CrossRefPubMed Cabodi S et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res. 2006;66(9):4672–80.CrossRefPubMed
21.
go back to reference Cheng CH et al. Blockade of v-Src-stimulated tumor formation by the Src homology 3 domain of Crk-associated substrate (Cas). FEBS Lett. 2004;557(1–3):221–7.CrossRefPubMed Cheng CH et al. Blockade of v-Src-stimulated tumor formation by the Src homology 3 domain of Crk-associated substrate (Cas). FEBS Lett. 2004;557(1–3):221–7.CrossRefPubMed
Metadata
Title
Overexpression of CASS4 promotes invasion in non-small cell lung cancer by activating the AKT signaling pathway and inhibiting E-cadherin expression
Authors
Ailin Li
Weiwei Zhang
Huifang Xia
Yuan Miao
Haijing Zhou
Xiupeng Zhang
Qianze Dong
Qingchang Li
Xueshan Qiu
Enhua Wang
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5411-5

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine